The targeting of oncogenic ‘driver’ kinases with small molecule inhibitors has proven to be a highly effective therapeutic strategy in selected non-small cell lung cancer (NSCLC) patients. However, ac
Research on the mechanism by which cancer-associated fibroblasts (CAFs) promote EGFR-TKI resistance in non-small cell lung cancer (NSCLC) via secretory proteins
Cisplatin (DDP) is the first-line chemotherapeutic agent against lung cancer. However, the therapeutic effect of DDP loses over time due to the acquired drug resistance in non-small cell lung cancer (
